Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Använda Telehealth för att åtgärda alkoholmissbruk i HIV-vård (ReACH3)

17 september 2026 uppdaterad av: Christopher W. Kahler, Brown University

This project will test the effects of a telehealth counseling program on reducing alcohol use and improving HIV viral control among people with HIV who drink heavily. In total, 600 heavy drinkers with HIV will be assigned to either (a) a single session of brief counseling on alcohol use or (b) brief counseling plus referral to a telehealth counseling program that includes multiple sessions of counseling by videoconferencing and text messaging support. To understand the effects of the program, participants' alcohol use, HIV outcomes, and health will be assessed over a 2-year period.

Studieöversikt

Detaljerad beskrivning

The purpose of the proposed study is to test the real-world effectiveness of the ReACH (Reducing Alcohol use and related Comorbidities in HIV care) telehealth counseling protocol in a pragmatic Hybrid Type 1 effectiveness-implementation randomized trial. The study will recruit 600 heavy-drinking PLWH from four federally-qualified health centers in geographically distinct regions across the U.S, which provide services to over 14,000 PLWH. Upon completing enrollment, participants will be randomized to receive either single-session brief intervention (BI) by phone with referral to local treatment when appropriate or BI plus referral to ReACH telehealth counseling (TC). Participants will complete follow-ups through 24 months after baseline to assess longer-term changes in drinking and health outcomes. The study will test the hypothesis that TC compared to BI will result in (a) reduced number of drinks consumed per week and frequency of heavy drinking and (b) increased odds of having an undetectable viral load at 12- and 24-month follow-ups. Secondary outcomes include self-reported ART adherence, engagement in condomless sex with non-exclusive partners, frequency of other substance use, phosphatidylethanol levels (a biomarker of recent alcohol use), and Veterans Aging Cohort Study index scores. The study also will examine potential moderators of TC effectiveness. As a secondary aim, implementation measures corresponding to aspects of the Dynamic Sustainability Framework will be assessed including implementation outcomes of acceptability, appropriateness, and feasibility guided by Proctor's Implementation Outcomes Framework. Thus, this pragmatic Hybrid Type 1 trial will help establish the real-world effectiveness of the ReACH TC intervention while also providing key implementation-related measures and outcomes that will inform future ReACH TC scale up and sustainability.

Studietyp

Interventionell

Inskrivning (Faktisk)

226

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Rhode Island
      • Providence, Rhode Island, Förenta staterna, 02912
        • Brown University

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • In care for HIV at one of 4 participating federally qualified health centers, report at least one heavy drinking day (4+ drinks) or average more than 7 drinks per week in the past 30 days

Exclusion Criteria:

  • need for supervised alcohol detoxification, as indicated by having a history of severe withdrawal symptoms such as seizures and delirium tremens.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Brief intervention

A brief alcohol intervention lasting about 10 minutes, delivered after the baseline assessments.

Brief alcohol intervention delivered by telephone or videoconferencing focusing on advising participants to reduce drinking

Experimentell: Brief Intervention plus Telehealth Counseling

A brief alcohol intervention followed by referral to a telehealth counseling protocol including 5 sessions of counseling based on Motivational Interviewing and delivered by videoconferencing. Telehealth counseling extends for up to two years and also includes a text messaging intervention to encourage reductions in drinking.

Brief alcohol intervention delivered by telephone or videoconferencing focusing on advising participants to reduce drinking

5 sessions of counseling on alcohol use based on Motivational Interviewing.

A daily and then monthly text messaging program designed to help participants monitor drinking, set goals, and reinforce successful reduction or abstinence.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Alcoholics drinks consumed per week
Tidsram: 12 months

Average number of alcoholic drinks consumed per week over the past 30 days

12 months
Alcoholics drinks consumed per week
Tidsram: 24 months

Average number of alcoholic drinks consumed per week over the past 30 days

24 months
Number of heavy drinking days
Tidsram: 12 months

Number of days consuming 4 or more drinks in a day over the past 30 days

12 months
Number of heavy drinking days
Tidsram: 24 months

Number of days consuming 4 or more drinks in a day over the past 30 days

24 months
Proportion of participants with a detectable HIV viral load
Tidsram: 12 months

Viral load test result that indicates HIV virus is detectable in the blood

12 months
Proportion of participants with a detectable HIV viral load
Tidsram: 24 months

Viral load test result that indicates HIV virus is detectable in the blood

24 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of the past 30 days adherent to antiretroviral therapy
Tidsram: 12 months

Antiretroviral therapy adherence as assessed by self-report

12 months
Proportion of the past 30 days adherent to antiretroviral therapy
Tidsram: 24 months

Antiretroviral therapy adherence as assessed by self-report

24 months
Condomless sex with non-steady partners
Tidsram: 12 months

Number of days in the past 30 having condomless sex with a non-steady partner

12 months
Condomless sex with non-steady partners
Tidsram: 24 months

Number of days in the past 30 having condomless sex with a non-steady partner

24 months
Veterans Aging Cohort Study (VACS) index total score
Tidsram: 12 months

Index of physiologic health calculated using HIV viral load, CD4 cell counts, liver function, creatinine, hemoglobin, platelets, white blood cell count, and height/weight (for body mass index). Higher scores indicate greater physiologic injury and risk for mortality.

12 months
Veterans Aging Cohort Study (VACS) index total score
Tidsram: 24 months

Index of physiologic health calculated using HIV viral load, CD4 cell counts, liver function, creatinine, hemoglobin, platelets, white blood cell count, and height/weight (for body mass index). Higher scores indicate greater physiologic injury and risk for mortality.

24 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Christopher Kahler, PhD, Brown University School of Public Health

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

22 juni 2021

Primärt slutförande (Faktisk)

13 september 2026

Avslutad studie (Faktisk)

13 september 2026

Studieregistreringsdatum

Först inskickad

2 september 2020

Först inskickad som uppfyllde QC-kriterierna

8 september 2020

Första postat (Faktisk)

14 september 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

21 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 2P01AA019072 (U.S.S. NIH-anslag/kontrakt)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Data will be shared through the National Data Archive. We also will post de-identified data used in the primary analyses of trial outcomes after those have been published.

Tidsram för IPD-delning

Data in the NDA will be available 6 months after the first participants are recruited and will remain in there.

Kriterier för IPD Sharing Access

Investigators can access date in the NDA using the available portal. We will allow access to the outcomes data to all through Brown's data archive once the outcome paper is published.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • ANALYTIC_CODE

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera